Sofinnova Venture Partners XI, L.P.
Follow-ons only
Follow-ons only: first sale Sep 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $500M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Global
01 · Thesis
No thesis found on the firm's website yet.
02 · Initial check
$5M to $8.33M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Maha Katabi, PhD, CFA, General Partner
- Jim Healy, MD, PhD, Managing Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideSofinnova is a healthcare investment firm focused on life science investing, primarily therapeutics, investing in late preclinical and clinical therapeutic companies across the U.S. and Europe.
Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade.
https://www.sofinnova.com/about/
06 · Sources
Last verified: Oct 28, 2026